Breast Cancer Core Needle Biopsy Market By Type of Needle (Automated Biopsy Needles, Manual Biopsy Needles), By Guidance System (Ultrasound-Guided Biopsy, Mammography-Guided Biopsy, MRI-Guided Biopsy, Stereotactic Biopsy), By End-User (Hospitals, Diagnostic Laboratories, Oncology Clinics, Research Institutes), By Procedure Type (Fine Needle Aspiration Biopsy, Core Needle Biopsy), and By Region; Global Insights & Forecast (2023 – 2030)

As per Intent Market Research, the Breast Cancer Core Needle Biopsy Market was valued at USD 0.6 Billion in 2024-e and will surpass USD 1.7 Billion by 2030; growing at a CAGR of 14.8% during 2025-2030.

The breast cancer core needle biopsy market is growing as breast cancer remains one of the most diagnosed cancers globally. Core needle biopsy is a crucial procedure for obtaining tissue samples from breast masses, enabling accurate diagnosis and appropriate treatment planning. As healthcare systems and technologies evolve, the demand for minimally invasive, accurate, and reliable biopsy procedures has increased. The advancements in needle designs, biopsy techniques, and imaging guidance systems have made this procedure safer and more efficient. Additionally, the growing awareness of early cancer detection and the shift towards personalized treatment strategies are driving the adoption of core needle biopsy as a preferred diagnostic tool.

Automated Biopsy Needles Are the Largest Segment Due to Efficiency

The automated biopsy needle segment is the largest in the breast cancer core needle biopsy market. These needles offer several advantages over manual devices, including improved precision, reduced procedure time, and enhanced safety for both patients and clinicians. Automated biopsy needles provide a quick and efficient sampling process by automatically triggering the tissue collection once positioned correctly. This minimizes the need for multiple attempts, which reduces patient discomfort and procedure complications.

The demand for automated biopsy needles is also rising due to the growing preference for minimally invasive procedures that require less recovery time and offer greater accuracy. As breast cancer diagnostic technologies evolve, the automated biopsy needle continues to be a critical tool for clinicians, especially in hospitals and oncology centers that deal with high volumes of cases. The integration of automated systems with advanced imaging technologies like ultrasound and mammography further strengthens their position as the primary choice for breast cancer diagnosis.

Ultrasound-Guided Biopsy is Fastest Growing Owing to Non-Invasiveness

The ultrasound-guided biopsy system is the fastest-growing segment within the guidance systems used for breast cancer core needle biopsies. Ultrasound offers real-time imaging capabilities, which allows clinicians to visualize the tissue and the needle’s precise location during the procedure. This minimizes the risks associated with misplacement and ensures accurate tissue sampling. Ultrasound-guided biopsies are preferred due to their non-invasiveness, lower cost, and absence of radiation, unlike mammography-guided or MRI-guided biopsies.

Furthermore, the ultrasound guidance system is highly portable, making it suitable for various clinical settings, including diagnostic laboratories and oncology clinics. The growing preference for non-invasive and cost-effective diagnostic procedures has further propelled the use of ultrasound guidance in core needle biopsies. The technology's ability to rapidly deliver high-quality results in real-time is key to its growing adoption, especially in emerging healthcare markets.

Hospitals Lead the End-User Segment Due to High Patient Volume

Hospitals represent the largest end-user segment in the breast cancer core needle biopsy market. Hospitals, with their robust infrastructure, large patient volumes, and multidisciplinary teams, are the primary setting for performing breast cancer biopsies. They have the capacity to adopt advanced biopsy technologies, including automated systems and sophisticated guidance techniques like ultrasound and mammography. Additionally, hospitals offer comprehensive care, from diagnostics to treatment, making them essential hubs for breast cancer management.

Hospitals benefit from economies of scale, enabling them to invest in high-cost technologies such as advanced biopsy needles and imaging systems. Furthermore, hospitals often house specialized oncology departments that focus on early cancer detection and intervention, increasing the need for precise and reliable biopsy procedures. The integration of core needle biopsy into routine clinical workflows in hospitals ensures high accessibility and more widespread use.

Core Needle Biopsy is the Most Common Procedure for Diagnosis

Core needle biopsy is the most common and preferred procedure for diagnosing breast cancer, owing to its ability to provide larger and more representative tissue samples compared to fine needle aspiration (FNA). Core needle biopsy is instrumental in confirming malignancy and determining the type and extent of the cancer, providing critical information that guides treatment decisions. The larger tissue samples collected also help pathologists to evaluate the tumor’s characteristics more thoroughly, such as hormone receptor status and HER2 expression.

This diagnostic capability is particularly important in the context of breast cancer, where the treatment approach—whether surgery, chemotherapy, or targeted therapies—depends on the biopsy findings. Core needle biopsy is less invasive than traditional surgical biopsies, offers faster results, and has a lower complication rate, making it the preferred choice for clinicians and patients alike.

North America Dominates the Market Due to Advanced Healthcare Infrastructure

North America holds the largest share of the breast cancer core needle biopsy market, driven by the high prevalence of breast cancer and the advanced healthcare infrastructure in the region. The United States, in particular, has a robust healthcare system with widespread access to cutting-edge diagnostic tools, including automated biopsy devices and advanced imaging guidance systems. The region also benefits from a strong focus on early cancer detection, as well as high awareness levels among the general population regarding the importance of screening.

Furthermore, North America is home to several key players in the medical device industry, which continually invest in developing innovative biopsy technologies. The high volume of breast cancer cases and the availability of reimbursement policies for diagnostic procedures further support the dominance of North America in the global market. The demand for minimally invasive diagnostic procedures, along with continuous research and development efforts, will maintain North America’s leading position in the breast cancer core needle biopsy market.

Competitive Landscape and Leading Companies

The competitive landscape of the breast cancer core needle biopsy market is highly concentrated, with several prominent companies focusing on technological advancements and product development. Leading players such as Hologic, Inc., Medtronic, and Becton Dickinson and Company dominate the market. These companies are constantly innovating to offer improved biopsy solutions, including automated biopsy needles, advanced imaging guidance systems, and enhanced patient comfort features.

In addition to product innovation, strategic collaborations, mergers, and acquisitions play a key role in strengthening the market positions of these companies. For instance, partnerships with hospitals and research institutions help expand product reach and enable clinical validation of new technologies. The market is also witnessing a trend towards hybrid solutions that integrate multiple biopsy techniques and guidance systems, providing more comprehensive diagnostic capabilities. As demand for breast cancer diagnostic solutions increases, competition in the market will continue to intensify, with companies striving to offer the most accurate, cost-effective, and patient-friendly solutions.

List of Leading Companies:

• Becton Dickinson and Company
• Hologic, Inc.
• Boston Scientific Corporation
• Medtronic
• Thermo Fisher Scientific
• Cook Medical
• CooperSurgical
• Galini SRL
• Cardinal Health, Inc.
• AngioDynamics
• Mammotome (Devicor Medical Products, Inc.)
• C.R. Bard (Acquired by Becton Dickinson)
• Stryker Corporation
• Medi-Globe GmbH
• GE Healthcare

Recent Developments:

• Hologic, Inc. announced the launch of its next-generation breast biopsy system, designed to enhance precision and comfort during core needle biopsies, with a focus on improving patient outcomes.
• Medtronic received FDA approval for its new core needle biopsy device, which offers advanced imaging compatibility and improved tissue sampling capabilities, optimizing the diagnosis of breast cancer.
• Boston Scientific Corporation expanded its product line by acquiring a leading developer of biopsy technologies, enhancing its ability to offer comprehensive solutions for breast cancer diagnosis.
• Becton Dickinson and Company revealed a collaboration with several leading research institutions to develop next-generation biopsy devices aimed at increasing accuracy in breast cancer detection.
• C.R. Bard unveiled an upgraded version of its automated biopsy system, promising quicker procedure times and reduced patient discomfort, further positioning itself as a leader in breast cancer diagnostics.

Report Scope: